Drugs / hiHep bioartificial liver therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05035108 | Sep 2021 → Nov 2030 expected | hepatocellular carcinoma | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hiHep bioartificial liver therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05035108 ↗ |
| Modality | Cell therapy | “The bioartificial liver device consists of clinical-grade human-induced hepatocytes (hiHep) generated from human fibroblasts via transdifferentiation.” NCT05035108 ↗ |